United States: FDA Releases Draft Guidance on Dissemination of Reprints of Peer Reviewed Journal Article

Companies should consider filing written comments on the Draft Guidance; the deadline for comment submission will be approximately April 20, 2008.

On February 15, 2008, the U.S. Food and Drug Administration (FDA) issued a news release announcing the availability for public comment of a Draft Guidance on dissemination of reprints of peer reviewed medical journal articles and other information about unapproved uses of approved new drugs and approved or cleared medical devices. (See http://www.fda.gov/bbs/topics/NEWS/2008/NEW01798.html; http://www.accessdata.fda.gov/scripts/oc/ohrms/advdisplay.cfm.) Such unapproved uses are generally referred to as "off-label" uses, because the FDA approved "label" defines and generally limits the scope of what can be communicated about an approved product by a regulated entity, such as a drug or device manufacturer, at least in a promotional context. Moreover, in assessing the Draft Guidance, it is important to observe that it does not purport to regulate the dissemination of any information by third parties, such as medical and scientific journals, which are truly independent of the drug or device manufacturer. Nor does the Draft Guidance in any way restrict the ability of a licensed practitioner to use an approved drug or device for any purpose, subject to whatever constraints might exist under applicable standards of medical practice.

The draft guidance—"Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices"—evoked criticism even before it was issued. On November 30, 2007, Congressman Henry Waxman, Chairman of the U.S. House of Representatives Committee on Oversight and Government Reform, who had obtained an internal agency draft of the draft guidance, sent a letter to FDA Commissioner Andrew von Eschenbach objecting to its release. (http://oversight.house.gov/story.asp?ID=1641.) The letter suggested, among other things, that then-impending draft guidance was part of a concerted effort by the Bush administration to create a "large loophole" that would effectively allow pharmaceutical and device manufacturers to engage in widespread marketing and promotion of approved drugs for unapproved uses. A careful review of the draft guidance suggests, however, that it is a measured—perhaps even overly restrictive—response to the widely acknowledged public health need for physicians to be provided high quality scientific information about "off-label uses or treatment regimens" that "may be important and may even constitute a medically recognized standard of care." (Draft Guidance at 4 .) Indeed, in certain fields such as oncology, off-label use is often the rule rather than the exception; the ability to provide timely information to the oncology community about high-quality data on off-label uses, and the corresponding need to provide reimbursement for such uses, is widely understood as being a substantial public health imperative. (See, e.g., American Society for Clinical Oncology, "Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications," J. Clin. Oncol. 24: 3206-3208 (July 1, 2006).) Moreover, the Draft Guidance does not appear to be a radical departure from existing law, as Congressman Waxman's "loophole" characterization suggests. On the contrary, although the Draft Guidance has numerous shortcomings in its own right, it appears to be a legitimate attempt by FDA to maintain some continuity in this area of the law in view of the recent "sunsetting" of the statutory and regulatory safe harbor for dissemination of qualifying "off-label" materials under the Food and Drug Administration Modernization Act of 1997. (See Draft Guidance at 2-3.)

Off-Label Dissemination Criteria

In the Draft Guidance, FDA identifies several criteria for determining whether and when dissemination of reprints of peer reviewed scientific journal articles is permitted and, hence, when such dissemination will not be deemed by FDA to be evidence that the manufacturer "intends" to promote its product for an unapproved use. Put somewhat differently, these standards will help FDA determine whether the dissemination of the off-label information is "promotional," in which event it is subject to FDA's prohibition against off-label promotion, or whether, instead, it amounts to "scientific speech" that is categorically beyond FDA's regulatory jurisdiction, or whether, even if technically within FDA's jurisdiction, regulation of the reprint dissemination by FDA cannot be squared with the requirements of the First Amendment. (See, e.g., Washington Legal Foundation v. Friedman, 13 F. Supp. 2d 51 (D.D.C. 1998), appeal dismissed and judgment vacated in part by Washington Legal Foundation v. Henney, 202 F.3d 331 (D.C.Cir.2000).) The Draft Guidance imposes significant constraints of the dissemination of medical or scientific journal articles about off-label uses.

Expert Editorial Board

The medical or scientific journal article must be published by an organization that has an independent editorial board composed of experts in the subject of the article. The expert editorial board is required to review and objectively select, reject or provide comments about proposed articles. Moreover, the publisher must have in place and adhere to a publicly stated conflict of interest policy, requiring full disclosure of conflicts of interest or "biases" for all authors, contributors or editors associated with the organization.

Peer Review

The medical or scientific journal article must be peer reviewed and published in accordance with the peer review procedures of the organization.

Special Supplements Not Permitted

The medical or scientific journal article must not appear in a special supplement or other manufacturer-funded publication.

Adequate and Well-Controlled Clinical Investigations

The information in the medical or scientific journal article should address "adequate and well-controlled clinical investigations that are considered scientifically sound by experts with scientific training and experience to evaluate the safety or effectiveness" of the product. In other words, FDA is importing the statutory "substantial evidence" standard that is applied to studies submitted in support of product approval or that is required by FDA to support promotional advertising claims to determine when dissemination of a reprint is "non-promotional" and justified. Perhaps more than anything else in the Draft Guidance, this criterion raises policy and legal concerns that should be addressed in the comment period.

Not False or Misleading

The medical or scientific journal article must not be false or misleading. One way the article might be misleading is if it is "inconsistent with the weight of credible evidence derived from adequate and well-controlled clinical investigations," e.g., where there exist a significant number of contradictory studies. It would also be considered misleading if the article had been withdrawn by the journal or disclaimed by the author, or where it discusses a study that FDA has previously told the company does not meet the standards for an adequate and well-controlled clinical investigation.

No Significant Risk to Public Health

The use discussed in the article must not pose a significant risk to the public health. There is no mention by FDA of any risk/benefit balancing in this criterion.

Disqualified Publications

Certain publications, such as letters to the editor, abstracts, reports of Phase I trials in healthy volunteers, and reference publications that contain little or no substantive discussion of the relevant investigation or data are categorically disqualified from being disseminated.

Manner of Dissemination

In order to qualify under this guidance, dissemination of a medical or scientific journal article should be: (i) in the form of an unabridged reprint or copy; (ii) accompanied by the product's FDA approved labeling; (iii) accompanied by, or already include in its text, a "comprehensive bibliography" of the adequate and well-controlled studies published to date about the particular off-label use that is the subject of the article; (iv) accompanied by, in cases where the conclusions of the article being disseminated, have been "specifically called into question" by another article or text, "a representative publication that reaches contrary or different conclusions"; and (v) distributed separately from any promotional information.

Accompanying Disclosures

The medical or scientific journal article should be accompanied by a "prominently displayed and permanently affixed statement" that discloses: (i) the uses discussed are not approved by FDA; (ii) the interest in the product of the manufacturer that is disseminating the information; (iii) any author who has a financial interest in the product or who is receiving compensation from the manufacturer; (iv) any person known to the manufacturer who has provided funding; and, importantly, (v) any significant risks or safety concerns known to the manufacturer concerning the unapproved use that are not discussed in the article. These resemble the "fair balance" disclosure standards that ordinarily apply to promotional communications.

No Discussion by Sales

In order to avoid being characterized as "promotional," FDA also recommends that sales representatives who disseminate otherwise qualifying off-label information refrain from discussing it in any way and refer any inquiries from doctors to the company's medical affairs department.

The criteria proposed by FDA on the permissible dissemination of medical or scientific articles about "off-label" uses, while welcome, still appear to impose significant burdens on the appropriate and lawful dissemination of such information in the public interest. Companies should consider filing written comments with FDA respecting the Draft Guidance. The deadline for comment submission is 60 days from the date of publication in the Federal Register, which is approximately April 20, 2008 (as the Federal Register Notice announcing the availability of the Draft Guidance has not yet been published).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions